
Manufacturer: Diffia AS, Sommerrogata 17, 0255 Oslo, Norway

Medical Device

Electronic Instructions for Use available at https://www.diffia.com/ifu

UDI: Basic UDI-DI 7073284NIMBLESW8H

CE-marked
Regulatory status: Medical device under Regulation (EU) 2017/745 (MDR). Not yet placed on the market as a CE-marked Class IIa device. See §2 for details.
Nimble is a tool your healthcare team uses to follow you up between visits. You use NimblePeople (via native app or website) to answer questions and send information to your careteam, who review it and decide on any care you may need. Nimble does not give you adiagnosis or treatment, and it does not replace contact with your healthcare professional.
Nimble is not for emergencies. If you need urgent help, contact your healthcare provider or call your local emergency number.
Follow your healthcare professional’s advice. Nimble supports your care, but a qualified clinician always reviews your information and makes the decisions.
Tell your care team if your symptoms get worse, if you feel unwell, or if you have not heard back from them when you expected to.
The sections written mainly for patients are 3 (what Nimble is for), 8 (who it is for), 11 (warnings) and 13 (when to contact your healthcare professional). The other sections contain technical and clinical detail for your healthcare provider.
Product name
Nimble
Device type
Software as a Medical Device (SaMD)
Version
2026.5
Software versions covered
All released software versions sharing the same intended purpose, unless otherwise stated in a deployment-specific addendum.
Risk class
Class IIa (MDR Annex VIII, Rule 11)
Basic UDI-DI
7073284NIMBLESW8H
Manufacturer
Diffia AS, Sommerrogata 17, 0255 Oslo, Norway
Regulatory status: Medical device under Regulation (EU) 2017/745 (MDR). Nimble is currently placed on the market as a Class I device under the manufacturer's self-declaration. This Instructions for Use applies to Nimble as a Class IIa device and shall take effect upon issuance of a CE certificate by a Notified Body.
The conformity assessment for Class IIa classification is currently in progress. Nimble is not yet placed on the market as a CE-marked Class IIa device. This Instructions for Use will be updated to include the CE mark and Notified Body number once the certificate has been issued.
Nimble is a Software as a Medical Device (SaMD) used by licensed healthcare professionals to monitor and follow up patients in specialist, secondary, or general care, by collecting structured patient-reported and clinician-entered data and presenting it to the supervising clinician for review.
The software enables healthcare professionals to operate digital follow-up pathways within manufacturer-validated functional frameworks (structured questionnaires and patient-reported outcome capture, threshold-based visual indicators, structured patient overviews, secure asynchronous patient–clinician communication, and - where established - interface to the patient's electronic health record). Within these validated frameworks, healthcare professionals configure pathway content and threshold values for their clinical context, while safety-critical functionality remains within boundaries defined and validated by the manufacturer.
Nimble is intended to support clinician-guided care, blended care (combining digital and in-person interactions), and structured remote follow-up where clinically appropriate. The software supports monitoring and follow-up by presenting patient-reported data, threshold-based indicators, and trends to the supervising clinician for review.
The software does not perform autonomous diagnosis, triage, or treatment decisions. All clinical judgement and responsibility remain with the supervising healthcare professional. All outputs require independent clinical interpretation by an authorised healthcare professional before any action is taken.
Nimble is intended to support clinicians in delivering structured digital follow-up pathways for patients with chronic or complex conditions where remote patient monitoring and patient-reported outcome capture form part of accepted clinical care. This includes, but is not limited to, conditions in the following areas:
The software does not embed condition-specific diagnostic algorithms and does not determine treatment pathways. The clinical indication for use in any specific deployment is defined by the prescribing healthcare professional within the manufacturer-validated functional framework.
The intended clinical benefits of Nimble include:
All clinical benefits are contingent on appropriate clinical supervision and correct configuration by a licensed healthcare professional within the manufacturer-validated functional framework.
Nimble performs the following functions in support of its intended purpose:
The software does not perform diagnostic computations, autonomous clinical assessments, or physiological measurements. All performance is contingent on correct configuration by a licensed healthcare professional within the manufacturer-validated functional framework.
Adults (≥18 years) - primary intended patient population. Nimble is primarily intended for use by patients aged 18 years and above who are under active specialist, secondary, or general care follow-up.
Adolescents (approximately 13–17 years) - permitted under conditions. Use of Nimble in adolescents aged approximately 13 to 17 years is permitted only where explicitly defined in a deployment-specific Instructions for Use addendum issued by the treating institution under documented clinical governance, under clinician supervision, and with appropriate consent.
Children (under 13 years) - not intended for independent use. Nimble is not intended for independent use by children under 13 years of age. Where a clinical pathway involves a child under 13, data may be submitted by a designated next of kin or representative on the child's behalf under the same conditions as the adolescent tier; the child shall not interact with the patient-facing module independently.
Healthcare environment: Nimble Clinic is intended for use in specialist, secondary, and general care institutions, including hospital outpatient departments, specialty clinics, general practice offices, and virtual healthcare settings.
Home and community environment under clinician supervision: Nimble People is intended for use by patients in their home or other non-clinical settings, under supervision of a licensed healthcare professional, as part of a digitally supported care pathway initiated and managed by the treating institution.
Nimble Clinic is accessed via supported web browsers and as a native mobile application (iOS and Android). Nimble People is accessed via supported web browsers and as a native mobile application (iOS and Android), on commercially available devices with internet connectivity. The device is not intended for offline use.
Nimble must not be used for:
The software shall always be used as an adjunct to established clinical practice.

The following limitations apply to Nimble and shall be understood by all users prior to use:
Patients shall consult their supervising healthcare professional if:
Nimble is not a substitute for direct clinical contact and shall not be used in situations requiring immediate medical attention. In such situations, patients shall contact their healthcare provider directly or, in the event of an emergency, the national emergency medical service.
Residual risks associated with Nimble have been identified and assessed through the manufacturer's risk management process in accordance with ISO 14971. The following residual risks remain after implementation of risk control measures and are considered acceptable. Users shall be aware of the following:
The outputs:
Performance and limitations
Nimble is a presentation and alerting software. The software does not perform diagnostic computations and does not have a measuring function. Indicators are generated based on pre-defined threshold values configured by the healthcare organisation. Indicator latency depends on the timing of the patient's data submission and system availability. Diffia AS monitors service availability and publishes statistics in accordance with the applicable service agreement with the healthcare organisation.
For safe and correct use, the following minimum requirements shall be met:
Nimble consists of two user interfaces:
Nimble Clinic is available to healthcare professionals and provides access to:
Nimble People is available to patients and next of kin and provides access to:
Detailed user guides are available within the respective Nimble Clinic and Nimble People sections of the help portal.
Nimble is a cloud-hosted Software as a Medical Device consisting of two integrated user interfaces and a shared backend services layer:
All communication between client and backend is encrypted using TLS 1.2 or later. Data is stored encrypted at rest. Authentication is performed via the healthcare organisation's identity provider (SSO/SAML) for healthcare professionals and via secure login with national electronic ID (BankID or equivalent) for patients. The platform operates with tenant isolation between healthcare organisations.
Nimble Clinic is accessible only via the Norwegian Health Network (Norsk helsenett, NHN). Nimble People is accessible over the public internet.
No local installation is required beyond download of the Nimble People mobile application from Apple App Store or Google Play Store.
Minimum hardware requirements:
Minimum software requirements - web (Nimble Clinic and Nimble People):
Minimum software requirements - native mobile applications (Nimble Clinic and Nimble People):
Network requirements:
EHR integration:
Nimble can be integrated with electronic health record systems for the exchange of structured health information. Integration has been validated against DIPS Arena. Other EHR systems may be supported following separate validation. Data exchange takes place via HL7 FHIR-based interfaces or equivalent standardised integration protocols agreed with the healthcare organisation. In the event of integration failure, data may become unavailable in the records system - see section 14 (Residual risks).
IT security:
In the event of a suspected data breach or unauthorised access, the healthcare organisation shall contact Diffia AS immediately at support@diffia.com.
Nimble is delivered as a software service (SaaS) and is updated on an ongoing basis. Updates may affect functionality. New versions are made available by agreement and with approval from the healthcare organisation. The healthcare organisation is responsible for informing clinical users in advance of new versions.
Expected service lifetime: Diffia AS commits to maintain and support Nimble for a defined minimum expected lifetime of 5 years from the date of MDR Class IIa certification, reassessed at each re-certification. In the event of end-of-life, customers will be notified at least 12 months in advance, and support and customer-data export will be provided in accordance with the manufacturer's device lifetime assessment.
Errors, incidents, or deviations shall be reported to:
Serious incidents that may be related to the use of Nimble shall additionally be reported to:
Reporting to the competent authority is regulated by MDR Article 87. The healthcare organisation and Diffia AS collaborate on notification as required.

Diffia AS
Sommerrogata 17
0255 Oslo, Norway
Website: www.diffia.com
Support: support@diffia.com
SRN: NO-MF-000027804
This Instructions for Use is made available in electronic form. For medical device software delivered as a service (SaaS) without physical packaging, electronic provision of instructions for use is permitted in accordance with Regulation (EU) 2021/2226, Article 2(1)(c), which applies to medical devices where the manufacturer can ensure that the user has access to the electronic instructions for use at all times.
The current version of this Instructions for Use is available at: https://www.diffia.com/ifu
The electronic version is the official version. In case of discrepancies between copies, the version available at the URL above prevails.
If you wish to receive a paper copy of this Instructions for Use, please contact the manufacturer at support@diffia.com. A paper copy will be sent free of charge within 7 working days.
Date of issue: June 11th, 2026 - IFU revision: 2026.5
This Instructions for Use is available in the following languages:
Language versions are maintained and controlled. The English master version prevails in case of discrepancies between language versions.
Markets: Nimble is currently made available in Norway.
Supplementary materials may include detailed user guides for Nimble Clinic and Nimble People, training resources, and operational guidance.
Supplementary materials do not replace this Instructions for Use. In case of discrepancy between supplementary materials and this Instructions for Use, this Instructions for Use prevails.
The following symbols are used in this Instructions for Use and in the labelling of Nimble in accordance with ISO 15223-1:2021 and Regulation (EU) 2017/745.

Caution - read the warnings and precautions carefully to avoid risk to the patient or user

Manufacturer of the medical device

Medical device

Consult the electronic instructions for use

Unique Device Identifier carrier

CE marking - the product complies with the applicable requirements of the MDR. The Notified Body number will be added adjacent to the CE marking upon issuance of the Class IIa certificate.